Salix Pharmaceuticals (NASDAQ: SLXP) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Salix Pharmaceuticals to related businesses based on the strength of its profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.
This table compares Salix Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Salix Pharmaceuticals Competitors||-547.39%||-39.23%||-21.46%|
This table compares Salix Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Salix Pharmaceuticals Competitors||$3.02 billion||$642.98 million||-30.87|
Salix Pharmaceuticals’ rivals have higher revenue and earnings than Salix Pharmaceuticals. Salix Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent ratings and recommmendations for Salix Pharmaceuticals and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Salix Pharmaceuticals Competitors||73||344||1003||29||2.68|
As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 23.72%. Given Salix Pharmaceuticals’ rivals higher probable upside, analysts clearly believe Salix Pharmaceuticals has less favorable growth aspects than its rivals.
Volatility & Risk
Salix Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Salix Pharmaceuticals’ rivals have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.
Insider & Institutional Ownership
65.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 10.7% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Salix Pharmaceuticals rivals beat Salix Pharmaceuticals on 8 of the 8 factors compared.
Salix Pharmaceuticals Company Profile
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.
Receive News & Ratings for Salix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.